Champions Oncology Names Angela Davies, M.D., Chief Medical Officer

     Champions Oncology Names Angela Davies, M.D., Chief Medical Officer

PR Newswire

HACKENSACK, N.J., Jan. 6, 2014

HACKENSACK, N.J., Jan. 6, 2014 /PRNewswire/ --Champions Oncology (OTC: CSBR),
a company engaged in the development of advanced technology solutions and
services to personalize the development and use of oncology drugs, today
announced the appointment of Angela Davies, M.D., as Chief Medical Officer.

Dr. Davies has demonstrated leadership and success in both academic clinical
practice and as an executive in the pharmaceutical industry. Previously, she
was Chief Medical Officer of OSI Pharmaceuticals where she led the clinical
development program for Tarceva® (erlotinib), as well as other pipeline
products, until the company's acquisition by Astellas Pharma. Earlier in her
career she was an Associate Professor of Medicine at the University of
California, Davis, where she practiced as a medical oncologist and was a
principal investigator on NCI sponsored and investigator initiated clinical
trials, specializing in thoracic malignancies and development therapeutics.

"Dr. Davies' blend of expertise will enable Champions Oncology to strengthen
our relationships with pharmaceutical companies looking to improve drug
discovery efforts as well as practicing oncologists seeking new treatment
options for patients," said Ronnie Morris, M.D., President of Champions
Oncology. "Her unique perspective is a great asset to Champions Oncology and
we are pleased to have her join the team."

"As a practicing oncologist, I saw many patients with limited treatment
options and highly aggressive cancers that left little time to test
therapies," added Dr. Davies. "The ability to evaluate potential treatments
with no risk to the patient and in a model highly correlative to the patient's
own tumor would have been a great tool for my practice. I look forward to
advancing this technology to enable oncologists, patients and drug developers,
to benefit from this approach." 

Dr. Davies most recently served as Chief Medical Officer of Novocure, where
she was responsible for the company's global clinical development and medical
safety programs, and worked closely with the Global Commercialization Team in
launching a newly approved medical device for the primary brain tumor,
recurrent glioblastoma. During her tenure at OSI, Dr. Davies was adjunct
clinical faculty at the University of Colorado Cancer Center. With her move to
the east coast, Dr. Davies will continue clinical practice as adjunct clinical
faculty at Smilow Cancer Hospital at Yale-New Haven. Dr. Davies has authored
or co-authored more than 60 publications in peer-reviewed journals and books
and more than 45 abstracts for scientific meetings. She has also held various
positions of leadership in the oncology community, including a position on
ASCO's Scientific Committee on thoracic malignancies as well as a position on
the editorial board of Clinical Lung Cancer. Dr. Davies obtained her medical
degree at McMaster University in Ontario, Canada, and her internal medicine
and medical oncology training at the University of Toronto and McMaster
University.

About Champions Oncology

Champions Oncology, Inc. is engaged in the development of advanced technology
solutions and services to personalize the development and use of oncology
drugs. The company's TumorGraft™ technology platform is a novel approach to
personalizing cancer care based upon the implantation of primary human tumors
in immune deficient mice followed by propagation of the resulting
engraftments, or TumorGrafts, in a manner that preserves the biological
characteristics of the original human tumor in order to determine the efficacy
of a treatment regimen. The company uses this technology in conjunction with
related services to offer solutions for two customer groups: Personalized
Oncology Solutions, in which results help guide the development of
personalized treatment plans, and Translational Oncology Solutions, in which
pharmaceutical and biotechnology companies seeking personalized approaches to
drug development can lower the cost and increase the speed of developing new
drugs. TumorGrafts are procured through agreements with a number of
institutions in the United States and overseas as well as through the
company's Personalized Oncology Solutions business. For more information,
please visit www.championsoncology.com.

SOURCE Champions Oncology

Website: www.championsoncology.com
Contact: Canale Communications, Ian Stone, Account Director, 619.849.5388,
ian@canalecomm.com
 
Press spacebar to pause and continue. Press esc to stop.